Order Summary

In order to access content on the Celltelligence Library, you must have an account.

The price for access is $0.00.

Do you have a discount code? Click here to enter your discount code.

Account Information Already have an account? Log in here


By selecting this, I agree to receive emails from celltelligence.com.

You will be granted access to your Celltelligence Library to view the full article after sign up.

PBCAR0191 Reports Improved Efficacy in CAR-T Relapse Patients; Precision to Evaluate PBCAR0191 with sLD; Updated Milestones for PBCAR19B and PBCAR269A; Precision Mid-Year 2022 Event

Here is a brief preview of this blast: On Wednesday, June 8, Precision BioSciences held their mid-year 2022 pipeline update event (press release / presentation), highlighting updated clinical results from PBCAR0191’s (allogeneic CD19 CAR-T) Ph1/2a study in CAR-T relapse patients. Additionally, management provided updated milestones for PBCAR19B (stealth CD19 CAR-T) and PBCAR269A (allogeneic BCMA CAR-T). Below, Celltelligence provides insights on Precision’s lymphodepleting strategy for PBCAR0191 in CAR-T relapse patients, while discussing PBCAR0191's potential regulatory pathway.

About The Author

The Celltelligence Team

Content Leads & Contributors
The Celltelligence team has combined experience in oncology, including cell therapy, CAR-T, immunology, microbiology, biochemistry, and other various fields in life sciences. Our team members include PhDs, industry veterans, and analysts tuned to The Street – all of whom help to create a more actionable service of delivering cell therapy intelligence.